Shruthi Acharya
Overview
Explore the profile of Shruthi Acharya including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
62
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Roy S, Chhaparwal Y, Kumar M, Acharya S, Chhaparwal S, Solomon M
J Int Soc Prev Community Dent
. 2024 Apr;
14(1):61-68.
PMID: 38559643
Aim: This comparative study evaluated the effectiveness and safety profile of topical amlexanox and triamcinolone for the management of erosive oral lichen planus (EOLP). Materials And Methods: This prospective, observational...
2.
Development of Epigallocatechin 3-gallate-Loaded Hydrogel Nanocomposites for Oral Submucous Fibrosis
Mehta C, Velagacherla V, Manandhar S, Nayak Y, Pai S, Acharya S, et al.
AAPS PharmSciTech
. 2024 Mar;
25(4):66.
PMID: 38519779
Oral submucous fibrosis (OSF) is a chronic progressive disease associated with increased collagen deposition and TGF-β1 release. The current therapy and management have been a limited success due to low...
3.
Mehta C, Paliwal S, Muttigi M, Seetharam R, Prasad A, Nayak Y, et al.
Inflammopharmacology
. 2023 Apr;
31(5):2349-2368.
PMID: 37106237
Oral submucous fibrosis (OSF) is a chronic, progressive, and precancerous condition mainly caused by chewing areca nut. Currently, OSF therapy includes intralesional injection of corticosteroids with limited therapeutic success in...
4.
Jain V, Parihar S, Acharya S, Acharya S
Work
. 2023 Mar;
76(1):3-10.
PMID: 36872823
Background: The risk of exposure to COVID-19 infection through droplets/aerosol in dental clinics has renewed focus on the utility and possible adverse effects of using personal protective equipment (PPE) on...
5.
Acharya S, Patil V, Ravindranath V, Kudva A, Nikhil K
J Med Life
. 2022 Apr;
15(3):368-373.
PMID: 35449990
Bone modifying agents (BMA) like bisphosphonates, antiangiogenic, and antiresorptive agents are widely used to manage bone diseases and cancer. Medication-related osteonecrosis of the jaw (MRONJ) is a potentially serious complication...
6.
Acharya S, Acharya S, Pentapati K, Thomson W
Community Dent Oral Epidemiol
. 2021 Feb;
49(6):574-580.
PMID: 33638567
Objectives: To measure utility ratings and quality-adjusted life-years(QALYs) for nicotine dependence-related health states using the standard gamble approach among a sample of dental patients; investigate the possible associations of nicotine...
7.
Kumar M, Acharya S, Vineetha R, Pai K
Med Pharm Rep
. 2021 Feb;
94(1):118-120.
PMID: 33629059
Bell's palsy is described as a type of facial paralysis, which is unilateral in 70% of the cases. Bell's palsy accounts for about 23% of bilateral facial paralysis. Here, we...
8.
Acharya S, Pai K, Acharya S
Med Pharm Rep
. 2020 Jun;
93(2):195-199.
PMID: 32478327
Objectives: To identify the potential risk factors for the occurrence of osteoradionecrosis (ORN) of the jaws among patients who have been treated with radiotherapy for head and neck malignancy. Methods:...
9.
Nivedita S, John E, Acharya S, DCosta V
Minerva Stomatol
. 2020 Feb;
68(6):297-302.
PMID: 32052618
Background: The decision of removing a non-impacted 3rd molar, unlike extraction of an impacted 3rd molar, is challenging for dentists as well as patients. This study investigates the pathologies affecting...
10.
Patil V, Acharya S, Vineetha R, Nikhil K
Oral Health Prev Dent
. 2020 Feb;
18(3):505-509.
PMID: 32016175
Purpose: Bisphosphonates and non-bisphosphonate antiangiogenic and antiresorptive agents are widely used in the management of bone diseases and cancer. A subset of patients receiving these drugs can manifest with medication-related...